CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Neurogene Inc is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Neurogene Inc
535 W 24Th Street, 5Th Floor
Phone: (206) 732-2133p:206 732-2133 NEW YORK, NY  10011  United States Ticker: NGNENGNE

This company was Merged or Acquired on 12/19/2023.
This is a Subsidiary, click here for the Parent Company

Business Summary
Neurogene Inc., formerly Neoleukin Therapeutics, Inc., is focused on developing genetic medicines for patients and their families affected by rare, devastating neurological diseases. The Company is developing novel approaches and treatments to address the limitations of conventional gene therapy in central nervous system disorders. The Company’s novel and proprietary EXACT transgene regulation platform technology allows for the delivery of therapeutic levels while limiting transgene toxicity associated with conventional gene therapy. The Company's product candidate, NGN-401, is an investigational adeno-associated virus (AAV9) gene therapy candidate for Rett syndrome purposefully designed and administered to maximize therapeutic activity while averting transgene overexpression toxicities. The Company is also developing NGN-101 for the treatment of CLN5 Batten disease. It is advancing multiple discovery-stage candidates leveraging its EXACT transgene regulation technology.

Scores and Ratings
FRISK®
Score
Z''
Score
PAYCE®
Score
DBT
Index
Moody's
Rating
Fitch
Rating
DBRS
Rating
YesYes-Yes---

Financials, News and Filings
Latest
Statement
Last
Audit

News
SEC
Filings
Bankruptcy
Filings
Suit &
Judgment
Filings
Tax
Lien
Filings
12/31/202312/31/2023YesYes---

Officers and Directors

Title

Name

Age
Title
Date
Start
Date
Chairman of the Board, Chief Executive Officer Rachel L.McMinn 50 12/18/2023 12/18/2023
President, Chief Financial Officer ChristineMikail 46 12/18/2023 12/18/2023
Senior Vice President, General Counsel Donna M.Cochener 48 2/15/2024 3/15/2022
5 additional Officers and Directors records available in full report.

Business Names
Business Name
AQXP
NGNE
NLTX

General Information
Number of Employees: 91 (As of 12/31/2023)
Outstanding Shares: 12,852,985 (As of 3/13/2024)
Shareholders: 41
Stock Exchange: NASD
Federal Tax Id: 980542593
Fax Number: (302) 655-5049


Copyright © 2024 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Friday, March 29, 2024